Efficacy and Safety of Inclisiran in Asian Patients: Results From ORION-18
{{output}}
Background: Management of low-density lipoprotein cholesterol (LDL-C) in Asia remains suboptimal, with ∼50% of patients who are treated with lipid-lowering therapies (LLTs) unable to achieve their guideline-recommended LDL-C goa... ...
